Removal of IgE through adsorption of IgE on a specially designed column after apheresis of blood has the potential to improve the severity of atopic dermatitis. In this study the investigators will treat patients with a severe form of Atopic dermatitis not responding or having to much side effects to systemic imunosuppressive treatment with this modality.
Patients will be treated with immunoadsorption on 4 consecutive days week 1 and three consecutive days week 5 and week 9. The clinical improvement and histological and serological tests will be evaluated.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
immunoadsorptions
UZ Leuven
Leuven, Belgium
RECRUITINGclinical improvement (The improvement of Atopic dermatitis will be evaluated with different scales including SCORAD, EASI, LIS, DLQI)
The improvement of Atopic dermatitis will be evaluated with different scales including SCORAD, EASI, LIS, DLQI
Time frame: one year
histological improvement and IgE tissue levels
we will evaluate the reduction of IgE and Fc epsilon RI expression in skin and total IgE in blood
Time frame: one year
Correlation between the therapeutic response and serum markers of disease activity .
we will evaluate serum levels and biomarkers such as TARC , MDC and TSLP during the course of the treatment
Time frame: one year
Effect of the treatment on positivity of skin prick tests.
we will evaluate skin prick reaction to dilution series of a previously positive allergen before and after treatment )
Time frame: one year
Evaluation of length of improvement
we will evaluate the duration of improvement after the last immunoadsorption and investigate if there is a correlation with drop in total IgE and / or biomarkers. The/ usefulness of supplemental adsorptionsessions will be investigated if there is an indication.
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.